Open AccessThai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy
Author(s) -
Reshmie Ramautarsing,
Jasper van der Lugt,
Meena Gorowara,
Stephen J. Kerr,
David M. Burger,
Kiat Ruxrungtham,
Praphan Phanuphak,
Surasith Chaithongwongwatthana,
Anchalee Avihingsa,
Nittaya Phanuphak
Publication year - 2011
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e328347f7e9
Subject(s) - lopinavir , lopinavir/ritonavir , cmin , medicine , ritonavir , cmax , pharmacokinetics , interquartile range , pregnancy , confidence interval , discontinuation , obstetrics , gestational age , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy , immunology , biology , genetics
To investigate whether Thai HIV-1-infected pregnant women require a dose increase of lopinavir/ritonavir (LPV/r) and to assess the safety and efficacy of the generic tablets during pregnancy.